Amedica reveals expected Q2 2015 financial results, FDA response: 5 key points

Amedica, a biomaterial company, expects to report second quarter 2015 revenue between $4.7 million and $4.9 million. The company also received an answer from the FDA about its Valeo C Interbody with CsC Osteo-Conductive Scaffolding.